Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in J Thorac Cardiovasc Surg

Retrieve available abstracts of 241 articles:
HTML format



Single Articles


    August 2022
  1. DELMAN AM, Turner KM, Wima K, Simon VE, et al
    Offering lung resection to current smokers: An opportunity for more equitable care.
    J Thorac Cardiovasc Surg. 2022;164:400-408.
    PubMed     Abstract available


    July 2022
  2. SULLIVAN KA, Farrokhyar F, Leontiadis GI, Patel YS, et al
    Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial.
    J Thorac Cardiovasc Surg. 2022;164:254-261.
    PubMed     Abstract available


  3. LIN J
    Commentary: Teach me to fish-spears, rods, and nets: Lymph node sampling during endobronchial ultrasound.
    J Thorac Cardiovasc Surg. 2022;164:263-264.
    PubMed    


  4. NA KJ, Kim YT
    Commentary: Targeted sampling during endobronchial ultrasound: Additional prerequisites for clinical implementation.
    J Thorac Cardiovasc Surg. 2022;164:262-263.
    PubMed    


  5. SATO M, Kobayashi M, Sakamoto J, Fukai R, et al
    The role of virtual-assisted lung mapping 2.0 combining microcoils and dye marks in deep lung resection.
    J Thorac Cardiovasc Surg. 2022;164:243-251.
    PubMed     Abstract available


    June 2022
  6. RUSCH VW
    Commentary: Surgical standardization in mesothelioma trials.
    J Thorac Cardiovasc Surg. 2022;163:1949-1950.
    PubMed    


  7. GIFFIN C, Kidane B
    Commentary: Less is maybe more: Sublobar resection in screen-detected lung cancers.
    J Thorac Cardiovasc Surg. 2022;163:1917-1918.
    PubMed    


  8. HASEGAWA S, Yokoi K, Okada M, Tanaka F, et al
    Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2022;163:1940-1947.
    PubMed     Abstract available


  9. GRIFFIN CM, van Berkel VH
    Commentary: A return trip to MARS: Less may be more when treating mesothelioma.
    J Thorac Cardiovasc Surg. 2022;163:1948-1949.
    PubMed    


    May 2022
  10. LIN J
    Commentary: Maximum standardized uptake value is no crystal ball for candidate selection for sublobar resection: The future is cloudy (ground-glass).
    J Thorac Cardiovasc Surg. 2022;163:1667-1668.
    PubMed    


  11. GILES AE, Kidane B
    Commentary: Toward precision surgery: Advances in defining sublobar resection candidacy.
    J Thorac Cardiovasc Surg. 2022;163:1666-1667.
    PubMed    


  12. MURAOKA Y, Yoshida Y, Nakagawa K, Ito K, et al
    Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection.
    J Thorac Cardiovasc Surg. 2022;163:1656-1665.
    PubMed     Abstract available


  13. ABDALLAH HM, Martinez-Meehan D, Lutfi W, Dhupar R, et al
    Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database.
    J Thorac Cardiovasc Surg. 2022;163:1669-1681.
    PubMed     Abstract available


    April 2022
  14. FURRER K, Weder W, Eboulet EI, Betticher D, et al
    Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
    J Thorac Cardiovasc Surg. 2022 Apr 18. pii: S0022-5223(22)00403.
    PubMed     Abstract available


  15. STARNES SL
    Commentary: Artificial intelligence for pulmonary nodules: Machines to diagnosis cancer.
    J Thorac Cardiovasc Surg. 2022;163:1506-1507.
    PubMed    


  16. ASHRAF SF, Yin K, Meng CX, Wang Q, et al
    Predicting benign, preinvasive, and invasive lung nodules on computed tomography scans using machine learning.
    J Thorac Cardiovasc Surg. 2022;163:1496-1505.
    PubMed     Abstract available


  17. KNEUERTZ PJ, Yudovich MS, Amadi CC, Bashian E, et al
    Pulmonary artery size on computed tomography is associated with major morbidity after pulmonary lobectomy.
    J Thorac Cardiovasc Surg. 2022;163:1521-1529.
    PubMed     Abstract available


  18. EKEKE CN, Russell KL, Murthy P, Guo ZS, et al
    Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    J Thorac Cardiovasc Surg. 2022;163:e313-e328.
    PubMed     Abstract available


    March 2022
  19. ISHIWATA T, Motooka Y, Ujiie H, Inage T, et al
    Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial.
    J Thorac Cardiovasc Surg. 2022 Mar 26. pii: S0022-5223(22)00344.
    PubMed     Abstract available


  20. CHIDI AP, Broderick SR
    Commentary: Perioperative systemic therapy in early-stage non-small cell lung cancer: The future is bright.
    J Thorac Cardiovasc Surg. 2022 Mar 24. pii: S0022-5223(22)00345.
    PubMed    


  21. HEIDEN BT, Subramanian MP, Liu J, Keith A, et al
    Long-term patient-reported outcomes after non-small cell lung cancer resection.
    J Thorac Cardiovasc Surg. 2022 Mar 12. pii: S0022-5223(22)00270.
    PubMed     Abstract available


  22. ELKIN PL, Mullin S, Tetewsky S, Resendez SD, et al
    Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Mar 10. pii: S0022-5223(22)00241.
    PubMed     Abstract available


  23. LIN J
    Commentary: Reading the voxels: A fortune teller's nomogram to invasiveness in stage IA lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:816-817.
    PubMed    


  24. BRUNELLI A
    Commentary: Ground glass opacity: Is it the Holy Grail?
    J Thorac Cardiovasc Surg. 2022;163:802-803.
    PubMed    


  25. QIU ZB, Zhang C, Chu XP, Cai FY, et al
    Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features.
    J Thorac Cardiovasc Surg. 2022;163:805-815.
    PubMed     Abstract available


  26. VILLENA-VARGAS J, Lutton EM, Mynard N, Nasar A, et al
    Safety of lung cancer surgery during COVID-19 in a pandemic epicenter.
    J Thorac Cardiovasc Surg. 2022 Mar 1. pii: S0022-5223(22)00222.
    PubMed     Abstract available


    February 2022
  27. ALTORKI N, Villena-Vargas J, Wakelee H
    Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.
    J Thorac Cardiovasc Surg. 2022 Feb 17. pii: S0022-5223(22)00202.
    PubMed    


  28. CASTRO PP, de Perrot M, Chua YC, Bezjak A, et al
    Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Feb 11. pii: S0022-5223(22)00195.
    PubMed     Abstract available


  29. STILES BM
    Commentary: Early stage epidermal growth factor receptor lung cancer: Skip to the good stuff?
    J Thorac Cardiovasc Surg. 2022 Feb 5. pii: S0022-5223(22)00125.
    PubMed    


  30. GRAY KD, Molena D
    Commentary: To cut is a chance to cure? Lessons to be learned from the PulMiCC trial.
    J Thorac Cardiovasc Surg. 2022;163:493-494.
    PubMed    


  31. VAN RAEMDONCK D, Van Cutsem E
    Commentary: A crusade against current pulmonary metastasectomy practice in colorectal cancer patients: Do the con arguments remain after the PulMiCC trial?
    J Thorac Cardiovasc Surg. 2022;163:491-492.
    PubMed    


  32. ALTORKI N, Vimolratana M
    Commentary: Surgery for ground-glass nodules: Free lunch or slippery slope?
    J Thorac Cardiovasc Surg. 2022;163:465-466.
    PubMed    


  33. PASS HI
    Commentary: Pulmonary metastasectomy efficacy: A game of clones?
    J Thorac Cardiovasc Surg. 2022;163:503-510.
    PubMed    


  34. BLUMENTHALER AN, Antonoff MB
    Commentary: The best outcomes for pulmonary metastasectomy come from picking the right patients.
    J Thorac Cardiovasc Surg. 2022;163:483-484.
    PubMed    


  35. TREASURE T, Dunning J, Williams NR, Macbeth F, et al
    Lung metastasectomy for colorectal cancer: The impression of benefit from uncontrolled studies was not supported in a randomized controlled trial.
    J Thorac Cardiovasc Surg. 2022;163:486-490.
    PubMed    


  36. ZHANG Y, Ma X, Shen X, Wang S, et al
    Surgery for pre- and minimally invasive lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:456-464.
    PubMed     Abstract available


  37. LIU Z, Yin J, Zhou Q, Yang J, et al
    Survival after pulmonary metastasectomy for relapsed osteosarcoma.
    J Thorac Cardiovasc Surg. 2022;163:469-479.
    PubMed     Abstract available


  38. MATSUURA Y, Ninomiya H, Ichinose J, Nakao M, et al
    Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:441-451.
    PubMed     Abstract available


    January 2022
  39. SEPESI B, Zhou N, William WN Jr, Lin HY, et al
    Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Jan 23. pii: S0022-5223(22)00089.
    PubMed     Abstract available


  40. WATANABE I, Hattori A, Fukui M, Matsunaga T, et al
    Pulmonary artery reconstruction for non-small cell lung cancer: Surgical management and long-term outcomes.
    J Thorac Cardiovasc Surg. 2022 Jan 22. pii: S0022-5223(22)00087.
    PubMed     Abstract available


  41. LANUTI M
    Commentary: Induction antiangiogenesis for stage IIIA-N2 non-small cell lung cancer is not the answer yet: Optimal induction for operable disease is a clear work in progress.
    J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00007.
    PubMed    


  42. LAZAR JF, Herrera LJ
    Commentary: Ablation and endobronchial ultrasound for treating early lung cancer: Two great technologies that may work great together!
    J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00009.
    PubMed    


  43. LINDEN PA
    Commentary: Spread the news: Spread through air spaces matters.
    J Thorac Cardiovasc Surg. 2022;163:285.
    PubMed    


  44. LIN J
    Commentary: Should we start spreading the news? Prognostic influence of spread through air spaces in early-stage lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:286-287.
    PubMed    


  45. DAVID EA
    Commentary: STAS is here to STAY.
    J Thorac Cardiovasc Surg. 2022;163:287-288.
    PubMed    


  46. ZHANG Y, Chen H
    Commentary: Is sublobar resection enough for ground-glass opacity-dominant lung adenocarcinoma?
    J Thorac Cardiovasc Surg. 2022;163:303-304.
    PubMed    


  47. ZHANG Y, Cao Y, Li H
    REPLY: THE CONTINUED DEBATE ON ROBOTIC SEGMENTECTOMY-AGREE TO DISAGREE.
    J Thorac Cardiovasc Surg. 2022;163:e99-e100.
    PubMed    


  48. JUNG W, Chung JH, Yum S, Kim K, et al
    The differential prognostic impact of spread through air spaces in early-stage lung adenocarcinoma after lobectomy according to the pT descriptor.
    J Thorac Cardiovasc Surg. 2022;163:277-284.
    PubMed     Abstract available


  49. CORSINI EM, Ripley RT
    Commentary: KRAS-mutant lung adenocarcinomas-a work in progress.
    J Thorac Cardiovasc Surg. 2022;163:e87-e88.
    PubMed    


  50. MA Z, Zhang Y, Deng C, Fu F, et al
    The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    J Thorac Cardiovasc Surg. 2022;163:e73-e85.
    PubMed     Abstract available


    December 2021
  51. CONNOLLY JG, Fiasconaro M, Tan KS, Cirelli MA Jr, et al
    Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 23. pii: S0022-5223(21)01818.
    PubMed     Abstract available


  52. TAKAMOCHI K, Suzuki K, Tsuboi M, Niho S, et al
    Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01714.
    PubMed     Abstract available


  53. SAVITCH SL, Grenda TR, Yi M, Till B, et al
    Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01716.
    PubMed     Abstract available


  54. ARNOLD BN, Antonoff MB
    Commentary: Optimizing resources in lung cancer survivorship.
    J Thorac Cardiovasc Surg. 2021 Dec 4. pii: S0022-5223(21)01691.
    PubMed    


  55. CHEN J, Soultanis KM, Sun F, Gonzalez-Rivas D, et al
    Outcomes of sleeve lobectomy versus pneumonectomy: A propensity score-matched study.
    J Thorac Cardiovasc Surg. 2021;162:1619-1628.
    PubMed     Abstract available


    November 2021
  56. SHENOY R, Okereke I
    Commentary: Lung cancer resections during the pandemic.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01651.
    PubMed    


  57. CHANG SH
    Commentary: Surgery versus stereotactic body radiation therapy for patients with renal dysfunction and non-small cell lung cancer: The answer is still not clear.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01647.
    PubMed    


  58. KESHAVA HB, Tan KS, Dycoco J, Huang J, et al
    Long-term assessment of efficacy with a novel thoracic survivorship program for patients with lung cancer.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01635.
    PubMed     Abstract available


    October 2021
  59. POULSON MR, Kenzik KM, Singh S, Pavesi F, et al
    Redlining, structural racism, and lung cancer screening disparities.
    J Thorac Cardiovasc Surg. 2021 Oct 14. pii: S0022-5223(21)01421.
    PubMed     Abstract available


  60. HANNA WC
    Commentary: Wedge versus segmentectomy-It is best to err on the side of caution.
    J Thorac Cardiovasc Surg. 2021;162:1254.
    PubMed    


    September 2021
  61. DELMAN AM, Van Haren RM
    Commentary: Mitigating lung cancer mortality in patients with end-stage renal disease.
    J Thorac Cardiovasc Surg. 2021 Sep 27. pii: S0022-5223(21)01389.
    PubMed    


  62. SAITO T, Murakawa T, Shintani Y, Okami J, et al
    Preoperative renal dysfunction and long-term survival after surgery for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Sep 10. pii: S0022-5223(21)01311.
    PubMed     Abstract available


  63. FARMER DM, Ripley RT
    Commentary: EGFR mutations lung adenocarcinoma-Is the driver removed with the lobe?
    J Thorac Cardiovasc Surg. 2021;162:675-676.
    PubMed    


  64. KHORFAN R, Cooke DT, Meguid RA, Backhus L, et al
    Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021;162:649-660.
    PubMed     Abstract available


  65. DENG C, Zhang Y, Ma Z, Fu F, et al
    Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2021;162:664-674.
    PubMed     Abstract available


    August 2021
  66. BRUNELLI A
    Commentary: Lobectomy should be the exception rather than the rule to resect screen-detected stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Aug 27. pii: S0022-5223(21)01253.
    PubMed    


  67. EGYUD M, Burt BM
    Commentary: The structure of structural racism revealed by lung cancer screening.
    J Thorac Cardiovasc Surg. 2021 Aug 24. pii: S0022-5223(21)01248.
    PubMed    


  68. SIENICKI E, Onaitis M
    Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance.
    J Thorac Cardiovasc Surg. 2021;162:474-475.
    PubMed    


  69. FU F, Zhang Y, Wang S, Li Y, et al
    Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules.
    J Thorac Cardiovasc Surg. 2021;162:451-459.
    PubMed     Abstract available


  70. YOSHIYASU N, Kojima F, Hayashi K, Bando T, et al
    Radiomics technology for identifying early-stage lung adenocarcinomas suitable for sublobar resection.
    J Thorac Cardiovasc Surg. 2021;162:477-485.
    PubMed     Abstract available


    July 2021
  71. PENNATHUR A, Brunelli A, Criner G, Keshavarz H, et al
    Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document.
    J Thorac Cardiovasc Surg. 2021 Jul 29. pii: S0022-5223(21)01129.
    PubMed     Abstract available


  72. CHUDGAR NP, Stiles BM
    Commentary: Adjuvant therapy in resected T1 2N0 non-small cell lung cancer: Surgeons should lead.
    J Thorac Cardiovasc Surg. 2021 Jul 14. pii: S0022-5223(21)01036.
    PubMed    


  73. WOODARD GA, Li A, Boffa DJ
    Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Jul 10. pii: S0022-5223(21)01032.
    PubMed    


  74. WANG SX, Marshall MB
    Commentary: A new hope: Do ADAURA trial results change the paradigm for treatment of resectable lung adenocarcinoma?
    J Thorac Cardiovasc Surg. 2021;162:293-294.
    PubMed    


  75. ANTONOFF MB, Morris VK
    Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients.
    J Thorac Cardiovasc Surg. 2021;162:e136-e138.
    PubMed    


  76. CAMERON RB
    Reply: Discussions regarding pulmonary metastasectomy are similar to American politics: Both are extremely polarizing, unsatisfying, inconclusive, and undertaken at your own peril.
    J Thorac Cardiovasc Surg. 2021;162:e135-e136.
    PubMed    


  77. HIRPARA DH, Kidane B
    Commentary: VATS, RATS, stats, and some caveats.
    J Thorac Cardiovasc Surg. 2021;162:269-270.
    PubMed    


  78. SIHAG S
    Commentary: Sarcomas and sarcomatoid tumors of the lung...not your average lung cancers.
    J Thorac Cardiovasc Surg. 2021;162:285-286.
    PubMed    


  79. JONES DR, Wu YL, Tsuboi M, Herbst RS, et al
    Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
    J Thorac Cardiovasc Surg. 2021;162:288-292.
    PubMed    


  80. CORSINI EM, Mitchell KG, Correa A, Morris VK, et al
    Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy.
    J Thorac Cardiovasc Surg. 2021;162:296-305.
    PubMed     Abstract available


  81. ROBINSON LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, et al
    Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas.
    J Thorac Cardiovasc Surg. 2021;162:274-284.
    PubMed     Abstract available


  82. KAMEL MK, Lee B, Harrison SW, Port JL, et al
    Sublobar resection is comparable to lobectomy for screen-detected lung cancer.
    J Thorac Cardiovasc Surg. 2021 Jul 1. pii: S0022-5223(21)01011.
    PubMed     Abstract available


    May 2021
  83. ISBELL JM, Li BT, Gomez DR
    The emerging role of local therapy in oligometastatic non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 May 29. pii: S0022-5223(21)00875.
    PubMed    


  84. DONINGTON JS
    Commentary: Why do we operate in metastatic lung cancer?
    J Thorac Cardiovasc Surg. 2021 May 8. pii: S0022-5223(21)00771.
    PubMed    


  85. WIGHTMAN SC, Kim AW
    Commentary: When less is more for lung cancers.
    J Thorac Cardiovasc Surg. 2021;161:1650-1651.
    PubMed    


  86. CERFOLIO RJ
    Commentary: Let us raise the bar higher for better patient outcomes.
    J Thorac Cardiovasc Surg. 2021;161:1649-1650.
    PubMed    


  87. WEKSLER B, Sullivan JL, Schumacher LY
    Randomized trial of bupivacaine with epinephrine versus bupivacaine liposome suspension in patients undergoing minimally invasive lung resection.
    J Thorac Cardiovasc Surg. 2021;161:1652-1661.
    PubMed     Abstract available


    April 2021
  88. FERNANDEZ R, Ahmad U
    Commentary: A new hope-neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Apr 27. pii: S0022-5223(21)00740.
    PubMed    


  89. BONNER SN, Wakeam E
    The volume-outcome relationship in lung cancer surgery: The impact of the social determinants of health care delivery.
    J Thorac Cardiovasc Surg. 2021 Apr 20. pii: S0022-5223(21)00593.
    PubMed    


  90. TONG BC, Gu L, Wang X, Wigle DA, et al
    Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Apr 9. pii: S0022-5223(21)00583.
    PubMed     Abstract available


  91. GROTH SS, Ripley RT
    Commentary: Cisplatin-induced nephrotoxicity following cytoreductive surgery and heated intraoperative chemotherapy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2021;161:1519-1520.
    PubMed    


  92. EBRIGHT MI
    Commentary: Acute kidney injury after intrapleural cisplatin: Minimizing collateral damage.
    J Thorac Cardiovasc Surg. 2021;161:1522-1523.
    PubMed    


  93. BRIBRIESCO A
    Commentary: Winning the battle for local control without losing war for survival against malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2021;161:1520-1522.
    PubMed    


  94. VARELA G
    Commentary: Extended disease, but still not the end for patients.
    J Thorac Cardiovasc Surg. 2021;161:1507-1508.
    PubMed    


  95. STILES BM
    Commentary: Think systemically, act locally.
    J Thorac Cardiovasc Surg. 2021;161:1505-1506.
    PubMed    


  96. VEERAMACHANENI NK
    Commentary: Ground-glass opacity-an unexpected silver lining.
    J Thorac Cardiovasc Surg. 2021;161:1481-1482.
    PubMed    


  97. YENDAMURI S
    Commentary: A picture really is worth a thousand words.
    J Thorac Cardiovasc Surg. 2021;161:1482-1483.
    PubMed    


  98. HOD T, Freedberg KJ, Motwani SS, Chen M, et al
    Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2021;161:1510-1518.
    PubMed     Abstract available


    March 2021
  99. ELY S, Jiang SF, Dominguez DA, Patel AR, et al
    Effect of thoracic surgery regionalization on long-term survival after lung cancer resection.
    J Thorac Cardiovasc Surg. 2021 Mar 20. pii: S0022-5223(21)00530.
    PubMed     Abstract available


  100. ANTONOFF MB, Sofocleous CT, Callstrom MR, Nguyen QN, et al
    The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases.
    J Thorac Cardiovasc Surg. 2021 Mar 6. pii: S0022-5223(21)00423.
    PubMed    


  101. TONG BC
    Commentary: Safety first!
    J Thorac Cardiovasc Surg. 2021;161:803-804.
    PubMed    


  102. RAYMOND DP
    Commentary: We need more surgeons!
    J Thorac Cardiovasc Surg. 2021;161:804-805.
    PubMed    


  103. IMAI T, Weksler B
    Commentary: Eurolung score as a predictor of long-term survival: It is not all about the tumor.
    J Thorac Cardiovasc Surg. 2021;161:788-789.
    PubMed    


  104. DONAHOE LL, Nason GJ, Bedard PL, Hansen AR, et al
    Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest.
    J Thorac Cardiovasc Surg. 2021;161:856-868.
    PubMed     Abstract available


  105. SHEMANSKI KA, Farias A, Lieu D, Kim AW, et al
    Understanding thoracic surgeons' perceptions of administrative database analyses and guidelines in clinical decision-making.
    J Thorac Cardiovasc Surg. 2021;161:807-816.
    PubMed     Abstract available


    February 2021
  106. IMAI T, Weksler B
    Commentary: Open or VATS? Roll up your sleeve.
    J Thorac Cardiovasc Surg. 2021;161:414-415.
    PubMed    


  107. CHUDGAR NP, Bott MJ
    Commentary: Minimally invasive sleeve lobectomy: Time to roll up our "sleeves" and learn something new?
    J Thorac Cardiovasc Surg. 2021;161:415-416.
    PubMed    


  108. RIPLEY RT
    Commentary: Drawing the target after shooting the arrow: The importance of trial design.
    J Thorac Cardiovasc Surg. 2021;161:443-444.
    PubMed    


  109. GERACI TC, Ng T
    Commentary: Overreliance of propensity-score matched studies in thoracic surgery.
    J Thorac Cardiovasc Surg. 2021;161:417-418.
    PubMed    


    January 2021
  110. VEERAMACHANENI NK
    Commentary: Computed tomography screening for lung cancer at large in China: Early cure or definitive overtreatment?
    J Thorac Cardiovasc Surg. 2021 Jan 13. pii: S0022-5223(21)00047.
    PubMed    


  111. YE T, Chen H
    Commentary: The ground-glass opacity: "The savior" for lung cancer?
    J Thorac Cardiovasc Surg. 2021 Jan 8. pii: S0022-5223(21)00014.
    PubMed    


    December 2020
  112. WATANABE Y, Hattori A, Nojiri S, Matsunaga T, et al
    Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Dec 29. pii: S0022-5223(20)33443.
    PubMed     Abstract available


  113. VAN RAEMDONCK D, Decaluwe H, De Leyn P, Nackaerts K, et al
    Commentary: Do we need to search for a patient's cigarettes or just count his or her wrinkles when counseling for lung cancer resection?
    J Thorac Cardiovasc Surg. 2020 Dec 25. pii: S0022-5223(20)33404.
    PubMed    


  114. HEIDEN BT, Subramanian MP, Puri V, Kozower BD, et al
    Striking a balance: Surveillance of non-small cell lung cancer after resection.
    J Thorac Cardiovasc Surg. 2020 Dec 10. pii: S0022-5223(20)33342.
    PubMed    


  115. AL NATOUR RH, He C, Clark MJ, Welsh R, et al
    The influence of tobacco load versus smoking status on outcomes following lobectomy for lung cancer in a statewide quality collaborative.
    J Thorac Cardiovasc Surg. 2020 Dec 10. pii: S0022-5223(20)33305.
    PubMed     Abstract available


  116. ABBAS AE
    Commentary: The value of close surveillance after lung cancer surgery: How absence of evidence is not evidence of absence.
    J Thorac Cardiovasc Surg. 2020 Dec 3. pii: S0022-5223(20)33213.
    PubMed    


  117. HENNON M, Groman A, Kumar A, Castaldo L, et al
    Correlation between perioperative outcomes and long-term survival for non-small lung cancer treated at major centers.
    J Thorac Cardiovasc Surg. 2020 Dec 3. pii: S0022-5223(20)33194.
    PubMed     Abstract available


  118. LIU C, Liao H, Guo C, Pu Q, et al
    Single-direction thoracoscopic basal segmentectomy.
    J Thorac Cardiovasc Surg. 2020;160:1586-1594.
    PubMed     Abstract available


    November 2020
  119. D'AMICO TA
    Commentary: Surgery for small cell lung cancer: This is the way.
    J Thorac Cardiovasc Surg. 2020 Nov 28. pii: S0022-5223(20)33173.
    PubMed    


  120. ZHOU N, Bott M, Park BJ, Vallieres E, et al
    Predictors of survival following surgical resection of limited-stage small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Nov 27. pii: S0022-5223(20)33137.
    PubMed     Abstract available


  121. ONAITIS M
    Commentary: Survival after small cell lung cancer resection: Small opportunity?
    J Thorac Cardiovasc Surg. 2020 Nov 24. pii: S0022-5223(20)33131.
    PubMed    


  122. SWANSON SJ
    Commentary: Find, resect, and treat: The evolving early-stage small cell lung cancer story.
    J Thorac Cardiovasc Surg. 2020 Nov 21. pii: S0022-5223(20)33080.
    PubMed    


  123. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    Respiratory strength and pectoralis muscle mass as measures of sarcopenia: Relation to outcomes in resected non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Nov 19. pii: S0022-5223(20)33059.
    PubMed     Abstract available


  124. SUZUKI K, Watanabe SI, Wakabayashi M, Saji H, et al
    A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer.
    J Thorac Cardiovasc Surg. 2020 Nov 12. pii: S0022-5223(20)33043.
    PubMed     Abstract available


  125. SESTI J, Paul S
    Commentary: Burn, baby, burn.
    J Thorac Cardiovasc Surg. 2020;160:1348-1349.
    PubMed    


  126. KIM SS, Bharat A
    Commentary: Video-assisted thoracoscopic surgery versus robotic assisted surgery: Are we asking the right question?
    J Thorac Cardiovasc Surg. 2020;160:1374-1375.
    PubMed    


  127. LIN J
    Commentary: The wizard of OS: Is overall survival better after sublobar resection versus stereotactic radiation or ablation?
    J Thorac Cardiovasc Surg. 2020;160:1358-1359.
    PubMed    


  128. LANUTI M
    Commentary: Can big data effectively answer important clinical questions?
    J Thorac Cardiovasc Surg. 2020;160:1361-1362.
    PubMed    


  129. SONG KJ, Flores RM
    Commentary: Robot-assisted segmentectomy is safe and expensive-What is the debate?
    J Thorac Cardiovasc Surg. 2020;160:1373-1374.
    PubMed    


  130. DENLINGER CE
    Commentary: To wedge or not to wedge.
    J Thorac Cardiovasc Surg. 2020;160:1359-1360.
    PubMed    


    October 2020
  131. TSUTANI Y, Handa Y, Shimada Y, Ito H, et al
    Comparison of cancer control between segmentectomy and wedge resection in patients with clinical stage IA non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Oct 22. pii: S0022-5223(20)32833.
    PubMed     Abstract available


  132. BEAMER S, D'Cunha J
    Commentary: Using the entire toolbox for improved survival in anaplastic lymphoma kinase-positive non-small cell lung cancer: The next normal?
    J Thorac Cardiovasc Surg. 2020 Oct 17. pii: S0022-5223(20)32858.
    PubMed    


  133. MUENYI C, Ng T
    Commentary: Sublobar resection, closing in as the standard in surgical management for a subgroup of patients with lung cancer.
    J Thorac Cardiovasc Surg. 2020 Oct 17. pii: S0022-5223(20)32848.
    PubMed    


  134. MUNIAPPAN A
    Commentary: One size does not fit ALK-Targeted therapy, local ablation of recurrence, and improved outcomes after resection of ALK-positive lung cancer.
    J Thorac Cardiovasc Surg. 2020 Oct 17. pii: S0022-5223(20)32856.
    PubMed    


  135. LANUTI M
    Commentary: Comparing sleeve lobectomy with pneumonectomy for central lung cancer: A randomized study will never be conducted.
    J Thorac Cardiovasc Surg. 2020 Oct 13. pii: S0022-5223(20)32818.
    PubMed    


  136. SCARCI M, Raveglia F
    Commentary: Ground-glass opacity-dominant lung cancer. Is every R0 wedge resection always a good wedge resection?
    J Thorac Cardiovasc Surg. 2020 Oct 13. pii: S0022-5223(20)32830.
    PubMed    


  137. PASS HI
    Commentary: Tasting individual ingredients of meso soup: Can 'omics bring out the flavor?
    J Thorac Cardiovasc Surg. 2020;160:1084-1085.
    PubMed    


  138. SEVERSON DT, De Rienzo A, Bueno R
    Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas.
    J Thorac Cardiovasc Surg. 2020;160:1078-1083.
    PubMed    


  139. RIPLEY RT
    Commentary: Filling up my truck from an oil tanker: Can big 'omic' data influence our clinical decisions?
    J Thorac Cardiovasc Surg. 2020;160:1086-1087.
    PubMed    


  140. DAVID EA, Atay SM
    Commentary: To scan or not to scan: No longer the question for mesothelioma patients after pleurectomy.
    J Thorac Cardiovasc Surg. 2020;160:1076-1077.
    PubMed    


  141. CAMERON RB
    Commentary: Mesothelioma: The Guinness world record holder in thromboembolism.
    J Thorac Cardiovasc Surg. 2020;160:1074-1075.
    PubMed    


  142. DEMMY TL
    Commentary: Positive pressure toward a negative trial?
    J Thorac Cardiovasc Surg. 2020;160:1062-1063.
    PubMed    


  143. CORSINI EM, Antonoff MB
    Commentary: Work in progress-Defining optimal surgical prehabilitation before lung resection.
    J Thorac Cardiovasc Surg. 2020;160:1060-1061.
    PubMed    


  144. DE LEON LE, Bravo-Iniguez CE, Fox S, Tarascio J, et al
    Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2020;160:1064-1073.
    PubMed     Abstract available


    September 2020
  145. HO H, Williamson C, Regis SM, Stock CT, et al
    Surgery and invasive diagnostic procedures for benign disease are rare in a large low-dose computed tomography lung cancer screening program.
    J Thorac Cardiovasc Surg. 2020 Sep 8. pii: S0022-5223(20)32573.
    PubMed     Abstract available


  146. RAKOVICH G, Bujold A
    The "multispecialty clinic": Toward a new paradigm in thoracic oncology?
    J Thorac Cardiovasc Surg. 2020;160:e176-e177.
    PubMed    


  147. MORI M, Geirsson A
    Reply from authors: Identifying lessons that could be generalized across different disease burdens.
    J Thorac Cardiovasc Surg. 2020;160:e133-e134.
    PubMed    


  148. SONG KJ, Flores RM
    REPLY: ROBOTIC-ASSISTED SEGMENTECTOMY: DOING IT SIMPLY BECAUSE WE CAN?
    J Thorac Cardiovasc Surg. 2020;160:e176.
    PubMed    


  149. MADARIAGA ML, Gaissert HA
    Reply from authors: The many benefits of a multidisciplinary evaluation of lung nodules.
    J Thorac Cardiovasc Surg. 2020;160:e177-e178.
    PubMed    


  150. ZHANG Y, Chen X, Li H
    Robotic or thoracoscopic segmentectomy: Each complements the other.
    J Thorac Cardiovasc Surg. 2020;160:e175.
    PubMed    


  151. VEERAMACHANENI NK
    Commentary: Minimally invasive sleeve lobectomy-from case report curiosity to standard of care?
    J Thorac Cardiovasc Surg. 2020;160:852-853.
    PubMed    


  152. CERFOLIO RJ
    Commentary: Why so many sleeve resections and pneumonectomies and why the nonabsorbable suture?
    J Thorac Cardiovasc Surg. 2020;160:847-848.
    PubMed    


  153. LAZZARO R, Patton B
    Commentary: Maximum surgery through minimal incisions.
    J Thorac Cardiovasc Surg. 2020;160:849-850.
    PubMed    


  154. MATTHEWS CR, Hess PJ
    Thirty-three, zero, nine.
    J Thorac Cardiovasc Surg. 2020;160:871-875.
    PubMed    


  155. CHU NQ, Liu R, Colby A, de Forcrand C, et al
    Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
    J Thorac Cardiovasc Surg. 2020;160:e159-e168.
    PubMed     Abstract available


  156. ZHANG Y, Jheon S, Li H, Zhang H, et al
    Results of low-dose computed tomography as a regular health examination among Chinese hospital employees.
    J Thorac Cardiovasc Surg. 2020;160:824-831.
    PubMed     Abstract available


    August 2020
  157. STILES BM
    Commentary: Overcoming the dangerous narrative of computed tomography screening for lung cancer.
    J Thorac Cardiovasc Surg. 2020 Aug 28. pii: S0022-5223(20)32464.
    PubMed    


  158. BRUNELLI A, Chaudhuri N, Kefaloyannis M, Milton R, et al
    Eurolung risk score is associated with long-term survival after curative resection for lung cancer.
    J Thorac Cardiovasc Surg. 2020 Aug 24. pii: S0022-5223(20)32431.
    PubMed     Abstract available


  159. CHEN KN
    Commentary: Not only safety but also efficacy is required in repeat pulmonary resection for second non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Aug 8. pii: S0022-5223(20)32360.
    PubMed    


  160. LIU C, Tian D, Pu Q
    Do not go too far when choosing intentional segmentectomy for small-sized lung cancers.
    J Thorac Cardiovasc Surg. 2020;160:e85-e86.
    PubMed    


  161. RAZI SS, Nguyen D, Villamizar N
    Reply from authors: Positive nodes after segmentectomy: Take a deep breath and give adjuvant treatment.
    J Thorac Cardiovasc Surg. 2020;160:e86-e87.
    PubMed    


  162. JEFFREY YANG CF, Berry MF
    Reply: The importance of appropriate selection for segmentectomy.
    J Thorac Cardiovasc Surg. 2020;160:e87.
    PubMed    


  163. LAZAR JF
    Commentary: How to "spot" a leopard: It's in the genes.
    J Thorac Cardiovasc Surg. 2020;160:e82-e83.
    PubMed    


  164. PATEL S, Kim AW
    Commentary: Standing on similar, but different, shoulders.
    J Thorac Cardiovasc Surg. 2020;160:e81-e82.
    PubMed    


  165. PENG S, Huang L, Zhao B, Zhou S, et al
    Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.
    J Thorac Cardiovasc Surg. 2020;160:585-592.
    PubMed     Abstract available


  166. HUANG J, Wang A, Kang G, Li D, et al
    Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery.
    J Thorac Cardiovasc Surg. 2020;160:e91-e93.
    PubMed    


  167. FAN L, Yang H, Yu L, Wang Z, et al
    Multicenter, prospective, observational study of a novel technique for preoperative pulmonary nodule localization.
    J Thorac Cardiovasc Surg. 2020;160:532-539.
    PubMed     Abstract available


    July 2020
  168. D'ANDRILLI A, Rendina EA
    Commentary: Second ipsilateral metachronous lung cancer: What to do?
    J Thorac Cardiovasc Surg. 2020 Jul 24. pii: S0022-5223(20)32224.
    PubMed    


  169. HATTORI A, Matsunaga T, Watanabe Y, Fukui M, et al
    Repeated anatomical pulmonary resection for metachronous ipsilateral second non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jul 16. pii: S0022-5223(20)32150.
    PubMed     Abstract available


  170. ZAMBETTI BR, Ng T
    Commentary: Patient frailty also drives long-term outcomes after R0 resection for lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jul 14. pii: S0022-5223(20)32079.
    PubMed    


  171. SUDARSHAN M, Murthy SC
    Commentary: Using nutritional scoring systems to predict outcomes after lung cancer surgery: Food for thought.
    J Thorac Cardiovasc Surg. 2020 Jul 13. pii: S0022-5223(20)32051.
    PubMed    


  172. BAZHENOVA L, Urbanic J, Onaitis M
    Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance?
    J Thorac Cardiovasc Surg. 2020 Jul 13. pii: S0022-5223(20)32054.
    PubMed    


  173. WALLACE AF, Weksler B
    Commentary: Food for thought: Assessing the influence of malnutrition in patients with lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jul 10. pii: S0022-5223(20)32042.
    PubMed    


  174. NELSON DB, Antonoff MB
    Commentary: The prognostic value of Kirsten rat sarcoma viral oncogene mutation for non-small cell lung cancer: One size does not always fit all.
    J Thorac Cardiovasc Surg. 2020 Jul 5. pii: S0022-5223(20)31990.
    PubMed    


  175. STILES BM, Sepesi B, Broderick SR, Bott MJ, et al
    Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jul 5. pii: S0022-5223(20)31987.
    PubMed    


  176. SALAZAR MC, Boffa DJ
    Commentary: The majority of minorities.
    J Thorac Cardiovasc Surg. 2020;160:272-273.
    PubMed    


  177. HAMMOUD ZT
    Commentary: Despair and disparity.
    J Thorac Cardiovasc Surg. 2020;160:275.
    PubMed    


  178. CORNWELL LD, Ripley RT
    Commentary: Beyond the eyeball test.
    J Thorac Cardiovasc Surg. 2020;160:285-286.
    PubMed    


  179. JONES GD, Tan KS, Caso R, Dycoco J, et al
    Time-varying analysis of readmission and mortality during the first year after pneumonectomy.
    J Thorac Cardiovasc Surg. 2020;160:247-255.
    PubMed     Abstract available


    June 2020
  180. TAKAHASHI M, Sowa T, Tokumasu H, Gomyoda T, et al
    Comparison of three nutritional scoring systems for outcomes after complete resection of non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jun 29. pii: S0022-5223(20)31751.
    PubMed     Abstract available


  181. MUNIAPPAN A
    Commentary: Through the looking glass-radiomics and evaluation of early lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jun 26. pii: S0022-5223(20)31771.
    PubMed    


  182. LIN J
    Commentary: Mind the gap: Adherence to quality measures for stage I/II non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jun 26. pii: S0022-5223(20)31753.
    PubMed    


  183. TANG A, Ahmad U, Toth AJ, Bourdakos N, et al
    Non-small cell lung cancer in never- and ever-smokers: Is it the same disease?
    J Thorac Cardiovasc Surg. 2020 Jun 18. pii: S0022-5223(20)31395.
    PubMed     Abstract available


  184. GILES AE, Kidane B
    Commentary: Know your enemy-Understanding futility in the battle against malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2020;159:2523-2524.
    PubMed    


  185. HOANG CD
    Commentary: Surgeon versus mesothelioma in a thoracic cage match.
    J Thorac Cardiovasc Surg. 2020;159:2522-2523.
    PubMed    


  186. ANDRADE R
    Commentary: Why do uniportal video-assisted thoracoscopic lobectomy?
    J Thorac Cardiovasc Surg. 2020;159:2496-2497.
    PubMed    


  187. BOFFA DJ, Salazar M
    Commentary: How surprising.
    J Thorac Cardiovasc Surg. 2020;159:2483-2484.
    PubMed    


  188. DE PERROT M
    Commentary: Is thoracic cage volume a new parameter for clinical staging in mesothelioma?
    J Thorac Cardiovasc Surg. 2020;159:2520-2521.
    PubMed    


  189. BURT BM, Lee HS, Raghuram AC, Strange C, et al
    Preoperative prediction of unresectability in malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2020;159:2512-2520.
    PubMed     Abstract available


  190. HYLTON DA, Turner S, Kidane B, Spicer J, et al
    The Canada Lymph Node Score for prediction of malignancy in mediastinal lymph nodes during endobronchial ultrasound.
    J Thorac Cardiovasc Surg. 2020;159:2499-2507.
    PubMed     Abstract available


  191. VIEIRA A, Bourdages-Pageau E, Kennedy K, Ugalde PA, et al
    The learning curve on uniportal video-assisted thoracic surgery: An analysis of proficiency.
    J Thorac Cardiovasc Surg. 2020;159:2487-2495.
    PubMed     Abstract available


    May 2020
  192. DONINGTON JS, Paulus R, Edelman MJ, Krasna MJ, et al
    Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 May 31. pii: S0022-5223(20)31276.
    PubMed     Abstract available


  193. SESTI J, Paul S
    Commentary: More science, less fortunetelling: Using radiomics to predict the invasiveness of lung cancer.
    J Thorac Cardiovasc Surg. 2020 May 25. pii: S0022-5223(20)31268.
    PubMed    


  194. DIMOU A, Nasarre C, Peterson YK, Pagano R, et al
    Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 May 25. pii: S0022-5223(20)31233.
    PubMed     Abstract available


  195. RAJARAM R, Rice DC, Li Y, Bruera E, et al
    Postoperative opioid use after lobectomy for primary lung cancer: A propensity-matched analysis of premier hospital data.
    J Thorac Cardiovasc Surg. 2020 May 16. pii: S0022-5223(20)31136.
    PubMed     Abstract available


  196. PASS HI
    Commentary: Not only SMART clinically, but translationally!
    J Thorac Cardiovasc Surg. 2020;159:2094-2095.
    PubMed    


  197. BRUNELLI A
    Commentary: The power of indeterminacy.
    J Thorac Cardiovasc Surg. 2020;159:2041.
    PubMed    


  198. SESTI J, Paul S
    Commentary: Known unknowns and unknown unknowns: The case of the indeterminate margin.
    J Thorac Cardiovasc Surg. 2020;159:2042.
    PubMed    


  199. CHEN-YOSHIKAWA TF
    Commentary: A journey of a thousand miles begins with a single step.
    J Thorac Cardiovasc Surg. 2020;159:2092-2093.
    PubMed    


  200. SRINATHAN S
    Is ventilatory efficiency the next new thing in prehabilitation?
    J Thorac Cardiovasc Surg. 2020;159:e323-e324.
    PubMed    


  201. WAKEAM E, Adibfar A, Stokes S, Leighl NB, et al
    Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma.
    J Thorac Cardiovasc Surg. 2020;159:2043-2054.
    PubMed     Abstract available


  202. MOLINA JC, Chaudry F, Menezes V, Ferraro P, et al
    Transvascular endosonographic-guided needle biopsy of intrathoracic lesions.
    J Thorac Cardiovasc Surg. 2020;159:2057-2065.
    PubMed     Abstract available


    April 2020
  203. DONINGTON J
    Commentary: Why does neoadjuvant therapy suddenly make sense for early stage non-small cell lung cancer?
    J Thorac Cardiovasc Surg. 2020 Apr 25. pii: S0022-5223(20)30999.
    PubMed    


  204. DENLINGER CE
    Commentary: Durable activity of a tyrosine kinase inhibitor in lung cancer.
    J Thorac Cardiovasc Surg. 2020 Apr 23. pii: S0022-5223(20)30985.
    PubMed    


  205. AZZOLI CG, Ng T
    Commentary: Preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: A stich in time, or delay from stiches?
    J Thorac Cardiovasc Surg. 2020 Apr 18. pii: S0022-5223(20)30967.
    PubMed    


  206. HOANG CD
    Commentary: Smoke or fire? Resected lung cancer in never-smokers.
    J Thorac Cardiovasc Surg. 2020 Apr 10. pii: S0022-5223(20)30795.
    PubMed    


  207. LIM K, Hsin MKY
    Commentary: Resection for small cell lung cancer should be offered more often, and preferably anatomical.
    J Thorac Cardiovasc Surg. 2020 Apr 6. pii: S0022-5223(20)30780.
    PubMed    


  208. JEFFREY YANG CF
    Commentary: Is surgery better than chemoradiation for T3N1M0 non-small cell lung cancer?
    J Thorac Cardiovasc Surg. 2020 Apr 6. pii: S0022-5223(20)30805.
    PubMed    


  209. HATTORI A, Suzuki K, Takamochi K, Wakabayashi M, et al
    Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Apr 6. pii: S0022-5223(20)30734.
    PubMed     Abstract available


  210. LANUTI M
    Commentary: Wedge resection for limited-stage small cell lung cancer: Not an acceptable modality for curative intent.
    J Thorac Cardiovasc Surg. 2020 Apr 5. pii: S0022-5223(20)30811.
    PubMed    


  211. PASS HI
    Commentary: "Hot" gene signatures for checkpoint response prediction: A very cool idea.
    J Thorac Cardiovasc Surg. 2020;159:1611-1612.
    PubMed    


  212. WAKEAM E, Kidane B
    Commentary: Picking the winners-Leaning into selection bias.
    J Thorac Cardiovasc Surg. 2020;159:1594-1595.
    PubMed    


  213. BLESSING WA, Colson YL
    Commentary: The checkpoint before checkpoint inhibitors.
    J Thorac Cardiovasc Surg. 2020;159:1614-1615.
    PubMed    


  214. PATEL S, Kim AW
    Commentary: TiME may actually tell good from bad.
    J Thorac Cardiovasc Surg. 2020;159:1613-1614.
    PubMed    


  215. PASS HI
    Discussion.
    J Thorac Cardiovasc Surg. 2020;159:1609-1610.
    PubMed    


  216. WOLF AS
    Discussion.
    J Thorac Cardiovasc Surg. 2020;159:1556.
    PubMed    


  217. SUBRAMANIAN MP
    Commentary: Much to do about nodules-Improving care with a multidisciplinary pulmonary nodule clinic.
    J Thorac Cardiovasc Surg. 2020;159:1569-1570.
    PubMed    


  218. PARK CH, Lee SM, Lee JW, Hwang SH, et al
    Hook-wire localization versus lipiodol localization for patients with pulmonary lesions having ground-glass opacity.
    J Thorac Cardiovasc Surg. 2020;159:1571-1579.
    PubMed     Abstract available


  219. NGUYEN DM, Villamizar N
    Commentary: Preoperative localization of "hard-to-find" pulmonary ground-glass opacity: There are more than one way to find the target.
    J Thorac Cardiovasc Surg. 2020;159:1581-1583.
    PubMed    


  220. MADARIAGA ML, Lennes IT, Best T, Shepard JO, et al
    Multidisciplinary selection of pulmonary nodules for surgical resection: Diagnostic results and long-term outcomes.
    J Thorac Cardiovasc Surg. 2020;159:1558-1566.
    PubMed     Abstract available


  221. FELMLY LM, Gibney BC
    Commentary: Biphasic malignant mesothelioma-Survival of the fittest.
    J Thorac Cardiovasc Surg. 2020;159:1596-1597.
    PubMed    


  222. SESTI J, Paul S
    Commentary: GGOogle maps for the adult lung.
    J Thorac Cardiovasc Surg. 2020;159:1580.
    PubMed    


  223. LOCOCO F, Torricelli F, Lang-Lazdunski L, Veronesi G, et al
    Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    J Thorac Cardiovasc Surg. 2020;159:1584-1593.
    PubMed     Abstract available


    March 2020
  224. OPITZ I
    Commentary: Surgery expanding to stage IV non-small cell lung cancer treatment?!
    J Thorac Cardiovasc Surg. 2020 Mar 31. pii: S0022-5223(20)30731.
    PubMed    


  225. MITCHELL KG, Farooqi A, Ludmir EB, Corsini EM, et al
    Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 25. pii: S0022-5223(20)30633.
    PubMed     Abstract available


  226. XIE D, Deng J, Gonzalez-Rivas D, Zhu Y, et al
    Comparison of video-assisted thoracoscopic surgery with thoracotomy in bronchial sleeve lobectomy for centrally located non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 25. pii: S0022-5223(20)30719.
    PubMed     Abstract available


  227. CHAN EG, Chan PG, Mazur SN, Normolle DP, et al
    Outcomes with segmentectomy versus lobectomy in patients with clinical T1cN0M0 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 23. pii: S0022-5223(20)30706.
    PubMed     Abstract available


  228. PATNAIK SK, Cortes EG, Kannisto ED, Punnanitinont A, et al
    Lower airway bacterial microbiome may influence recurrence after resection of early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 23. pii: S0022-5223(20)30631.
    PubMed     Abstract available


  229. RAMAN V, Jawitz OK, Yang CJ, Voigt SL, et al
    The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 22. pii: S0022-5223(20)30634.
    PubMed     Abstract available


  230. CHOI JJ, Huang J
    Commentary: How much is enough? The extent of resection in small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Mar 19. pii: S0022-5223(20)30588.
    PubMed    


  231. PASS HI
    Commentary: Lung cancer and dysbiosis: Debugging the studies for the future.
    J Thorac Cardiovasc Surg. 2020 Mar 19. pii: S0022-5223(20)30619.
    PubMed    


  232. ZHANG Y, Fu F, Hu H, Wang S, et al
    Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
    J Thorac Cardiovasc Surg. 2020 Mar 19. pii: S0022-5223(20)30625.
    PubMed     Abstract available


    February 2020
  233. HONG TH, Kim J, Shin S, Kim HK, et al
    Clinical outcomes of microscopic residual disease after bronchial sleeve resection for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Feb 29. pii: S0022-5223(20)30518.
    PubMed     Abstract available


  234. RAHOUMA M, Kamel M, Nasar A, Harrison S, et al
    Treatment of cT3N1M0/IIIA non-small cell lung cancer and the risk of underuse of surgery.
    J Thorac Cardiovasc Surg. 2020 Feb 24. pii: S0022-5223(20)30503.
    PubMed     Abstract available


  235. JAKLITSCH MT, Jacobson FL
    The future of lung cancer screening with low-dose computed tomography.
    J Thorac Cardiovasc Surg. 2020 Feb 19. pii: S0022-5223(20)30199.
    PubMed    


  236. NGUYEN DM, Villamizar N
    Commentary: Lower airway microbiome and non-small cell lung cancer: The beginning of a bug story.
    J Thorac Cardiovasc Surg. 2020 Feb 14. pii: S0022-5223(20)30382.
    PubMed    


  237. NELSON DB, Niu J, Mitchell KG, Antonoff MB, et al
    Perioperative outcomes among chronic opioid users who receive lobectomy for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020;159:691-702.
    PubMed     Abstract available


  238. BOTT MJ
    Commentary: Opioid dependence in the lobectomy patient: A hard pill to swallow.
    J Thorac Cardiovasc Surg. 2020;159:703-704.
    PubMed    


  239. BACIEWICZ FA JR
    Preoperative pulmonary rehabilitation.
    J Thorac Cardiovasc Surg. 2020;159:e147-e148.
    PubMed    


  240. LINDEN PA, Perry Y, Worrell S, Wallace A, et al
    Postoperative day 1 discharge after anatomic lung resection: A Society of Thoracic Surgeons database analysis.
    J Thorac Cardiovasc Surg. 2020;159:667-678.
    PubMed     Abstract available


    September 2019
  241. CAO C, Louie BE, Melfi F, Veronesi G, et al
    Outcomes of major complications after robotic anatomic pulmonary resection.
    J Thorac Cardiovasc Surg. 2019 Sep 18. pii: S0022-5223(19)31809.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: